• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Irritable Bowel Syndrome - Pipeline Review, Q1 2011 - Product Image

Irritable Bowel Syndrome - Pipeline Review, Q1 2011

  • ID: 1574110
  • February 2011
  • 67 pages
  • Global Markets Direct

Irritable Bowel Syndrome - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Irritable Bowel Syndrome - Pipeline Review, Q1 2011', provides an overview of the Irritable Bowel Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Irritable Bowel Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome. 'Irritable Bowel Syndrome - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Irritable Bowel Syndrome.
- A review of the Irritable Bowel Syndrome products under development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Irritable Bowel Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Irritable Bowel Syndrome
Irritable Bowel Syndrome Therapeutics under Development by Companies
Irritable Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Irritable Bowel Syndrome Therapeutics Development
Bristol-Myers Squibb Company
Abbott Laboratories
GlaxoSmithKline plc
Pharming Group N.V.
Albany Molecular Research, Inc.
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Pfizer Inc.
Salix Pharmaceuticals, Ltd.
Menarini Group
Paratek Pharmaceuticals, Inc.
Shire Plc
Callisto Pharmaceuticals, Inc.
Compugen Ltd.
Cosmo Pharmaceuticals S.p.A
Pharmos Corporation
Lexicon Pharmaceuticals, Inc.
New York Health Care, Inc.
Sucampo Pharmaceuticals, Inc.
Baylor College of Medicine
Alba Therapeutics Corporation
Ironwood Pharmaceuticals, Inc.
Respiratorius AB
Ocera Therapeutics, Inc.
JADO Technologies GmbH.
Avera Pharmaceuticals, Inc.
AmKor Pharma, Inc.
Tioga Pharmaceuticals, Inc.
Rose Pharma A/S
Giaconda Limited
Targacept, Inc.
N-Gene Research Laboratories, Inc.
Napo Pharmaceuticals, Inc.
Kemin Industries, Inc.
RaQualia Pharma Inc.
SK Bio-Pharmaceuticals
Universities/Institutes Involved in Irritable Bowel Syndrome Therapeutics Development
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Amitiza - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Asimadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Linaclotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesalazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Chinese Herbal Medicine Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Co-biotic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Desipramine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mosapride Citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Irritable Bowel Syndrome - Featured News
1. Nov 01, 2010: Ironwood And Forest Announce Positive Linaclotide Results From Second Phase III Trial In Irritable Bowel Syndrome With Constipation
2. Sep 14, 2010: AMRI Advances New Irritable Bowel Syndrome Treatment Towards IND Submission
3. Sep 13, 2010: Ironwood And Forest Announce Positive Linaclotide Results From Phase III Trial In Patients With Irritable Bowel Syndrome With Constipation
4. Aug 02, 2010: N30 Pharma Receives FDA Approval To Initiate Phase I Clinical Trial For N6022 For Treatment Of Asthma, COPD And IBD
5. Jun 03, 2010: Tioga Begins Phase III Trial Of Asimadoline In Irritable Bowel Syndrome
6. Jun 01, 2010: VBL To Present Anti-Inflammatory Properties Of VBL-201 At Keystone Symposium
7. May 05, 2010: Lexicon Presents Positive Outcome In IBS Patients Treated With LX1031
8. May 03, 2010: Ocera Demonstrates Proof Of Principle For Use Of Ast-120 In Treatment Of Non-Constipating Irritable Bowel Syndrome
9. May 03, 2010: ImmunoCellular Files Orphan Drug Application For ICT-107
10. May 03, 2010: NicOx Announces Presentation Of Phase III Blood Pressure Results For Naproxcinod At ASH Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Irritable Bowel Syndrome, 2011
Products under Development for Irritable Bowel Syndrome – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Abbott Laboratories, 2011
GlaxoSmithKline plc, 2011
Pharming Group N.V., 2011
Albany Molecular Research, Inc., 2011
Astellas Pharma Inc., 2011
Dong-A Pharmaceutical Co., Ltd., 2011
Eisai Co., Ltd., 2011
Pfizer Inc., 2011
Salix Pharmaceuticals, Ltd., 2011
Menarini Group, 2011
Paratek Pharmaceuticals, Inc., 2011
Shire Plc, 2011
Callisto Pharmaceuticals, Inc., 2011
Compugen Ltd., 2011
Cosmo Pharmaceuticals S.p.A, 2011
Pharmos Corporation, 2011
Lexicon Pharmaceuticals, Inc., 2011
New York Health Care, Inc., 2011
Sucampo Pharmaceuticals, Inc., 2011
Baylor College of Medicine, 2011
Alba Therapeutics Corporation, 2011
Ironwood Pharmaceuticals, Inc., 2011
Respiratorius AB, 2011
Ocera Therapeutics, Inc., 2011
JADO Technologies GmbH., 2011
Avera Pharmaceuticals, Inc., 2011
AmKor Pharma, Inc., 2011
Tioga Pharmaceuticals, Inc., 2011
Rose Pharma A/S, 2011
Giaconda Limited, 2011
Targacept, Inc., 2011
N-Gene Research Laboratories, Inc., 2011
Napo Pharmaceuticals, Inc., 2011
Kemin Industries, Inc., 2011
RaQualia Pharma Inc., 2011
SK Bio-Pharmaceuticals, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, 2011
Products under Development for Irritable Bowel Syndrome – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos